Cwm LLC Purchases 14,720 Shares of United Therapeutics Corporation $UTHR

Cwm LLC boosted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 160.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 23,909 shares of the biotechnology company’s stock after buying an additional 14,720 shares during the quarter. Cwm LLC’s holdings in United Therapeutics were worth $11,650,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB raised its holdings in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Harbor Capital Advisors Inc. bought a new stake in United Therapeutics during the 4th quarter worth about $48,000. Abich Financial Wealth Management LLC bought a new stake in United Therapeutics during the 3rd quarter worth about $44,000. WealthCollab LLC raised its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Finally, Rakuten Securities Inc. raised its holdings in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $471.91, for a total transaction of $10,617,975.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 414,295 shares of company stock valued at $217,625,176 over the last quarter. 10.30% of the stock is owned by insiders.

United Therapeutics Stock Performance

Shares of UTHR opened at $588.38 on Friday. The stock has a 50 day simple moving average of $526.73 and a 200 day simple moving average of $489.98. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $607.89. The firm has a market capitalization of $25.79 billion, a PE ratio of 21.09, a P/E/G ratio of 1.65 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period in the previous year, the firm earned $6.19 EPS. United Therapeutics’s quarterly revenue was up 7.4% compared to the same quarter last year. Equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Unusual bullish options flow — Traders bought 15,930 UTHR call options on Friday (about a 665% jump versus average call volume), indicating speculative or hedged bullish positioning that can amplify near-term upside or volatility.
• Positive Sentiment: Analyst target increases and constructive coverage — Multiple firms have raised price targets recently (examples cited include Morgan Stanley, Oppenheimer, BofA and RBC) and the consensus remains a “Moderate Buy” with an average target near $601.50, supporting positive investor sentiment. Analyst Coverage & MarketBeat Summary
• Neutral Sentiment: Small CEO sale disclosed — CEO Martine Rothblatt sold 75 shares (March 13) for roughly $40k; the size is immaterial to overall ownership and is unlikely on its own to drive stock direction. InsiderTrades Alert
• Neutral Sentiment: Institutional/hedge fund activity — Several funds adjusted positions (some added, some trimmed); UTHR remains heavily institutionally owned (~94%), which tends to moderate retail-driven swings. MarketBeat: Insider & Institutional Activity
• Negative Sentiment: Material insider selling by CEO — Martine Rothblatt sold 9,500 shares on April 15 (~$5.5M at ~$580.36), a significant reduction in her reported holding per filings; large insider sales can be perceived negatively by investors. SEC Filing: CEO Sale
• Negative Sentiment: Large EVP sale — EVP Paul A. Mahon sold 8,300 shares on April 16 for roughly $4.79M, a meaningful insider disposition that may pressure sentiment if more insider sales follow. SEC Filing: EVP Sale

Wall Street Analyst Weigh In

Several analysts have weighed in on UTHR shares. Morgan Stanley boosted their price objective on United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. TD Cowen boosted their price objective on United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Cantor Fitzgerald boosted their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Bank of America upped their price target on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Finally, HC Wainwright upped their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Ten investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $601.50.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.